EOLS News and Press, Evolus Inc.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective J...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™...

2024-06-21 07:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Launching in one of the five largest aesthetic toxin injectable markets in Europe 1 as part of the company’s geographic expansion strategy Evolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionals Evolus, In...

2024-06-06 08:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting May 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling idea...

2024-05-22 07:00:00 ET Summary Evolus is a facial beauty company that specializes in aesthetic neurotoxins, with its flagship product being Jeuveau. The company is expanding its product portfolio by adding dermal fillers through exclusive agreements with Evolysse and Estyme. T...

2024-05-20 16:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at all measured timepo...

David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit Evolus' flagship product, Jeuveau ® is the fastest growing aesthetic toxin in the U.S. for the last three years 1 Evolus...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The awar...